• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多药耐药基因(MDR1)多态性与初发肾移植患者环孢素吸收情况

Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients.

作者信息

Foote Clary J, Greer Wenda, Kiberd Bryce, Fraser Albert, Lawen Joseph, Nashan Bjorn, Belitsky Philip

机构信息

Department of Pathology, Queen Elizabeth II Health Sciences Centre/ Dalhousie University, Halifax, NS, Canada.

出版信息

Transplantation. 2007 May 27;83(10):1380-4. doi: 10.1097/01.tp.0000264197.88129.2e.

DOI:10.1097/01.tp.0000264197.88129.2e
PMID:17519790
Abstract

BACKGROUND

Several single nucleotide polymorphisms (SNPs) in the multidrug resistance (MDR1) gene may play a role in the interindividual variation of cyclosporine A (CsA) absorption in renal transplant patients.

METHODS

An analysis of CsA absorption measured by the dose- and weight-adjusted 4 hr area under the time-concentration curve, AUC(0-4)/mg doseCsA/kg, was conducted on day 3 after transplantation, in 69 de novo renal transplant patients who were genotyped for MDR1 SNPs. Follow-up pharmacogenomic analysis at 1 month posttransplant was performed utilizing dose- and weight-adjusted 2-hour postdose CsA concentration (C2).

RESULTS

AUC(0-4)/mg doseCsA/kg was significantly higher (P=0.024) in (C/C)3435 individuals than in a grouped population of (C/T)3435 and (T/T)3435 patients on postoperative day 3. G2677T variants were not significantly correlated with CsA absorption (P=0.084). The number of C3435-G2677 haplotypes was the best predictor of CsA exposure. At 1 month posttransplant, no correlation was seen between MDR1 SNPs and CsA exposure. The frequency of wild-type variants for C3435T and G2677T were 61% and 77.6%, respectively. SNPs at G2677T and C3435T loci were found to be in linkage disequilibrium.

CONCLUSIONS

MDR1 polymorphisms are associated with differences in CsA exposure only in the first posttransplant week.

摘要

背景

多药耐药(MDR1)基因中的几个单核苷酸多态性(SNP)可能在肾移植患者中环孢素A(CsA)吸收的个体间差异中起作用。

方法

对69例接受基因分型检测MDR1 SNP的初发肾移植患者,于移植后第3天进行CsA吸收分析,通过剂量和体重校正的4小时时间 - 浓度曲线下面积AUC(0 - 4)/mg剂量CsA/kg来测定。在移植后1个月进行随访药物基因组学分析,利用剂量和体重校正的给药后2小时CsA浓度(C2)。

结果

术后第3天,(C/C)3435个体的AUC(0 - 4)/mg剂量CsA/kg显著高于(C/T)3435和(T/T)3435患者的分组人群(P = 0.024)。G2677T变异与CsA吸收无显著相关性(P = 0.084)。C3435 - G2677单倍型数量是CsA暴露的最佳预测指标。移植后1个月,未发现MDR1 SNP与CsA暴露之间存在相关性。C3435T和G2677T野生型变异的频率分别为61%和77.6%。发现G2677T和C3435T位点的SNP处于连锁不平衡状态。

结论

MDR1多态性仅在移植后的第一周与CsA暴露差异相关。

相似文献

1
Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients.多药耐药基因(MDR1)多态性与初发肾移植患者环孢素吸收情况
Transplantation. 2007 May 27;83(10):1380-4. doi: 10.1097/01.tp.0000264197.88129.2e.
2
MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients.多药耐药基因1(MDR1)C3435T多态性与初治肾移植受者的环孢素水平相关。
Transplant Proc. 2006 Nov;38(9):2847-9. doi: 10.1016/j.transproceed.2006.08.120.
3
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.肾移植后CYP3A5和MDR1基因多态性与环孢素的药代动力学
Clin Pharmacol Ther. 2004 May;75(5):422-33. doi: 10.1016/j.clpt.2004.01.009.
4
Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.肾移植术后早期环孢素浓度与CYP3A5和MDR1基因多态性的相关性
Exp Clin Transplant. 2006 Jun;4(1):416-9.
5
Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients.氨氯地平而非多药耐药基因1(MDR1)多态性改变了日本肾移植受者中环孢素A的药代动力学。
Transplantation. 2003 Sep 15;76(5):865-8. doi: 10.1097/01.TP.0000084873.20157.67.
6
Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.肾移植受者中CYP3A5和MDR1基因的遗传多态性及其与他克莫司和环孢素血药浓度的相关性
Transplant Proc. 2009 Apr;41(3):840-2. doi: 10.1016/j.transproceed.2009.01.050.
7
Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.基因多态性对亚洲肾移植受者他克莫司给药有显著影响,但对环孢素给药无显著影响。
Transplant Proc. 2008 Jun;40(5):1690-5. doi: 10.1016/j.transproceed.2008.04.010.
8
Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.肾移植受者中环孢素A吸收曲线的演变:对起始期和维持期的纵向研究。
Nephrol Dial Transplant. 2006 Jan;21(1):197-202. doi: 10.1093/ndt/gfi113. Epub 2005 Oct 4.
9
A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.MDR1基因的2677A等位基因变体影响非索非那定的处置。
Clin Pharmacol Ther. 2004 Nov;76(5):418-27. doi: 10.1016/j.clpt.2004.08.002.
10
Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.接受环孢素和米芙治疗的肾移植受者的药代动力学和药效学
Transplant Proc. 2007 Sep;39(7):2160-2. doi: 10.1016/j.transproceed.2007.07.003.

引用本文的文献

1
Pharmacogenetic Study of the Impact of Single Nucleotide Polymorphisms on the Response to Cyclosporine in Psoriasis Patients.银屑病患者中,单核苷酸多态性对环孢素反应影响的药物遗传学研究。
Pharmaceutics. 2022 Nov 11;14(11):2441. doi: 10.3390/pharmaceutics14112441.
2
Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation.器官移植后使用钙调磷酸酶抑制剂的免疫抑制治疗中个体化剂量调整的生物标志物。
Acta Pharmacol Sin. 2019 Feb;40(2):151-159. doi: 10.1038/s41401-018-0070-2. Epub 2018 Jun 27.
3
Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients.
CYP3A4和MDR1基因(G2677T)多态性对埃及肾移植受者环孢素剂量需求的影响。
Mol Biol Rep. 2015 Jan;42(1):105-17. doi: 10.1007/s11033-014-3747-8. Epub 2014 Sep 21.
4
Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients.MDR1 基因 SNPs 及单体型与汉族肝移植受者他克莫司剂量需求的相关性研究。
PLoS One. 2011;6(11):e25933. doi: 10.1371/journal.pone.0025933. Epub 2011 Nov 14.
5
The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.药物遗传学和药物基因组学在银屑病治疗中的最新进展。
Mol Diagn Ther. 2010 Apr 1;14(2):81-93. doi: 10.1007/BF03256357.
6
Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.药物基因组学:在肾病患者中实现个体化治疗的新模式。
Clin Exp Immunol. 2010 Mar;159(3):268-80. doi: 10.1111/j.1365-2249.2009.04065.x. Epub 2009 Nov 24.